FLAVIN JOHN L 4
4 · Pyxis Oncology, Inc. · Filed Oct 15, 2021
Insider Transaction Report
Form 4
FLAVIN JOHN L
Director
Transactions
- Conversion
Common Stock
2021-10-13+2,388→ 171,610 total - Conversion
Series B Convertible Preferred Stock
2021-10-13−15,190→ 0 total→ Common Stock (2,388 underlying)
Footnotes (2)
- [F1]These shares of Series B Convertible Preferred Stock converted automatically and for no additional consideration into Common Stock on a 6.359-for-1 basis upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). The shares of Series B Convertible Preferred Stock had no expiration date.
- [F2]Includes 47,593 shares of restricted stock that are subject to vesting in six, substantially-equal quarterly installments beginning October 22, 2021, subject to the reporting person's continued service through the applicable vesting date.